
ALT This image contains an excerpt from the Research Summary "Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial” published in the New England Journal of Medicine. It includes a diagram of a complement involved in IgA nephropathy pathogenesis. There are illustrations for two treatment groups: "Ravulizumab" with 240 individuals and "Placebo" with 245 individuals. Additional text summarizes study demographics, noting 485 adults with a mean age of 42.5 years. A prompt to read the full Research Summary at NEJM.org sits at the bottom.

ALT Three panels showing the changes from baseline in 24-hour urinary protein-to-creatinine ratio. Panel A is a bar chart that shows the change from baseline in the 24-hour urinary protein-to-creatinine ratio at week 34 (primary end point). Panel B is a graph shows the change from baseline in the 24-hour urinary protein-to-creatinine ratio at weeks 10, 26, and 34; from the mixed model for repeated measures. Panel C is a bar chart that shows the percentage of patients with a 50% or greater reduction from baseline in the 24-hour urinary protein-to-creatinine ratio at weeks 10, 26, and 34.



































